GT Biopharma Inc. Common Stock

Go to GT Biopharma Inc. Common Stock Website

$3.35

(%)
Live
Previous Close

$3.345

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$4.6 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics f...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.

Related tickers: GTBP.

Read Full Article

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company’s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from Benzinga Pro. Cutera shares dipped 26.5% to $1.6899 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Murano Global Investments PLC (NASDAQ: MRNO) shares jumped 147.5% to $23.94 after falling 46% on Thursday. Nova LifeStyle, Inc. (NASDAQ: NVFY) surged 120% to $4.0301 after gaining around 22% on Thursday. BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 50.4% to $0.2256 after the company reported better-than-expected fourth-quarter earnings results. IMAC Holdings, Inc. (NASDAQ: BACK) gained 41.1% to $1.8204. Summit Midstream Partners, LP (NYSE: SMLP) surged 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million. Outlook Therapeutics, Inc. (NASDAQ: OTLK) gained 32.1% to $9.30 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD. GT Biopharma, Inc. (NASDAQ: GTBP) gained 27.6% to $4.86. Aemetis, Inc. (NASDAQ: AMTX) rose 21% to $6.21. Aemetis recently announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the carbon sequestration project and energy efficiency upgrades to the Keyes ethanol plant. Foresight Autonomous Holdings Ltd. (NASDAQ: ...

Related tickers: BCAN, ATER, MRNO, WS, BACK, IDN, YTEN, SLNA, CUTR, FRSX, ISPR, LULU, GTBP, BTDR, AIR, RETO, DNTH, FDX, SINT, EGOX, FL, OTLK, OCGN, LAAC, NKE, NKTX, ABTS, CGC, ANNX, GRDI, GRFS, LXEH, BNAI, BIOL, JOAN, ALAB, KC, LICY, AMTX, CZOO, SMLP, TROO, NVFY.

Read Full Article
Trending Tickers
DATS

XNAS

$1.24
(%)
LASE

XNAS

$2.10
(%)
NYCB

XNYS

$2.97
(%)
PACW

XNAS

$7.54
(%)
MLGO

XNAS

$0.00
(%)